Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341372 | 0.99 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL11902048 | 0.95 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL6651104 | 0.89 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL2039581 | 0.89 | KMT2A (0.42) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL6796558 | 0.86 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL377928 | 0.82 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL25797253 | 0.82 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL8933069 | 0.82 | FABP5 (0.42) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL11964044 | 0.82 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL3580338 | 0.81 | GPR119 (0.44) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186860-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | U.S. DEPARTMENT OF ENERGY | 2018-07-05 | — | — | US | disclosed |
| WO-2017044899-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| US-8877927-B2 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors | GRUNENTHAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012103113-A1 | PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C | GILEAD PHARMASSET, LLC (US) | 2012-08-02 | — | — | WO | disclosed |
| EP-2046797-B1 | FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-05-23 | — | — | EP | disclosed |
| US-20100010009-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2046797-A1 | FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | Amura Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008007127-A1 | FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| US-7119073-B2 | Peptides and their use as inhibitors of hepatitis C virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-10-10 | — | — | US | disclosed |
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-07-22 | — | — | US | disclosed |
| EP-1392721-A1 | PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002079234-A1 | PEPTIDES AND THEIR USE AS INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | CTRL, VIP, CTSC | KMT2A 4234/4885FABP5 2372/4885FABP7 2788/4885 |
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | KMT2A 4326/4885FABP5 823/4885FABP7 1750/4885 |
| US-20100010009-A1 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors | ABCB1, COLGALT1, SLC40A1 | KMT2A 3009/4885FABP5 2851/4885FABP7 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.